AstraZeneca today announced that a jury in the US District Court for the District of Massachusetts returned a verdict in favour of AstraZeneca in a Multi-District antitrust case filed by various purchaser groups challenging the previous settlement of Nexium patent litigation with Ranbaxy.
AstraZeneca is pleased with the jury’s verdict. The Company has always maintained that the plaintiffs’ alle
AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for IRESSA® (gefitinib) as a targeted monotherapy for the first line treatment of patients with advanced or metastatic epidermal growth factor receptor mutation positive (EGFRm) non-small cell lung cancer (NSCLC), as identified through a companion diagnostic test. The P
AstraZeneca and Eli Lilly and Company (Lilly) today announced enrolment of the first patient into AMARANTH, a Phase II/III study of an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer’s disease.
AstraZeneca today announced that MedImmune, its global biologics research and development arm, completed its acquisition of Definiens, a privately-held company that has pioneered a world-leading imaging and data analysis technology, known as Tissue Phenomics™, which dramatically improves the identification of biomarkers in tumour tissue.
Study met all primary endpoints against Stelara® (ustekinumab)
and placebo
Three pivotal studies form the basis for global regulatory filings, planned for 2015
AstraZeneca and Amgen today announced that AMAGINE-2TM, a pivotal, multi-arm Phase III trial evaluating two doses of brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, met its primary endpoints when c
AstraZeneca today announced that Duaklir® Genuair® (aclidinium bromide/formoterol fumarate 340/12 mcg) has been granted Marketing Authorisation by the European Commission (EC) to be used as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Forskningsportföljen i sen fas ligger långt före tidsplanen tack vare ökad produktivitet inom R&D, accelererade program och en målinriktad affärsutveckling; 14 potentiella nya läkemedel finns i fas III eller är under registrering; vi har potential för 14–16 ansökningar och 8–10 godkännanden under 2015–2016. En branschledande immuno-onkologiportfölj med 13 pågående kombinationsprövningar och 16
Updates on BRILINTA development programme and data from cardiovascular portfolio to be presented at American Heart Association (AHA) Scientific Sessions 2014
Världsdiabetesdagen 14 november: Sverige har hamnat på efterkälken när det gäller användning av nya diabetesläkemedel och ligger exempelvis långt efter Finland och Danmark1. En undersökning med över 2 000 svenskar med typ 2-diabetes visar dessutom att användningen av nya diabetesläkemedel varierar starkt beroende på var i Sverige man bor2. Kunskapen om olika diabetesbehandlingar är låg 2.
Brodalumab meets all primary and all key secondary endpoints Meets primary endpoint of superiority to Stelara® (ustekinumab) in achieving total skin clearance (PASI 100) Meets co-primary endpoints against placebo
AstraZeneca, with its global biologics research and development arm, MedImmune, will present new data from the company’s growing inflammation and autoimmunity portfolio at the American College of Rheumatology (ACR) 2014 Annual Meeting in Boston, Massachusetts, 14-19 November 2014.
More than 15 abstracts will be featured at the ACR meeting, providing evidence of the depth and continued progress
AstraZeneca today announced that it has entered into a definitive agreement with Aegerion Pharmaceuticals, Inc. to divest Myalept™ (metreleptin for injection), an orphan product that is indicated to treat complications of leptin deficiency in patients with generalised lipodystrophy.
Myalept is the first and only product approved in the US for the treatment of generalised lipodystrophy and it h
